↓ Skip to main content

Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, December 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?
Published in
Journal of Experimental & Clinical Cancer Research, December 2017
DOI 10.1186/s13046-017-0657-3
Pubmed ID
Authors

Luca Pompili, Carlo Leonetti, Annamaria Biroccio, Erica Salvati

Abstract

Telomeres are specialized nucleoprotein structures responsible for protecting chromosome ends in order to prevent the loss of genomic information. Telomere maintenance is required for achieving immortality by neoplastic cells. While most cancer cells rely on telomerase re-activation for linear chromosome maintenance and sustained proliferation, a significant population of cancers (10-15%) employs telomerase-independent strategies, collectively referred to as Alternative Lengthening of Telomeres (ALT). ALT mechanisms involve different types of homology-directed telomere recombination and synthesis. These processes are facilitated by loss of the ATRX or DAXX chromatin-remodeling factors and by abnormalities of the telomere nucleoprotein architecture. Although the functional consequences of telomerase and ALT up-regulation are similar in that they both prevent overall telomere shortening in tumors, these telomere maintenance mechanisms (TMMs) differ in several aspects which may account for their differential prognostic significance and response to therapy in various tumor types. Therefore, reliable methods for detecting telomerase activity and ALT are likely to become an important pre-requisite for the use of treatments targeting one or other of these mechanisms. However, the question whether ALT presence can confer sensitivity to rationally designed anti-cancer therapies is still open. Here we review the latest discoveries in terms of mechanisms of ALT activation and maintenance in human tumors, methods for ALT identification in cell lines and human tissues and biomarkers validation. Then, original results on sensitivity to rational based pre-clinical and clinical anti-tumor drugs in ALT vs hTERT positive cells will be presented.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 48 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 23%
Student > Ph. D. Student 10 21%
Student > Bachelor 4 8%
Student > Master 4 8%
Student > Doctoral Student 3 6%
Other 2 4%
Unknown 14 29%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 15 31%
Medicine and Dentistry 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Chemistry 3 6%
Agricultural and Biological Sciences 2 4%
Other 3 6%
Unknown 17 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2018.
All research outputs
#14,605,790
of 25,382,440 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#775
of 2,380 outputs
Outputs of similar age
#221,005
of 447,848 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#8
of 41 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,380 research outputs from this source. They receive a mean Attention Score of 4.8. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,848 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.